Expressing the sense of the House of Representatives that the United States should not waive intellectual property rights relating to COVID–19 vaccines or treatments.

H. Res. 484 · 117th Congress · Jun 17, 2021 · Lineage

RESOLUTION

that it is the sense of the House of Representatives that—

(1)

the policy of the United States should not be to waive valid intellectual property protections for COVID–19 vaccines or treatments, related manufacturing processes or technology, technology platforms used to develop COVID–19 vaccines or other medicines, or other related innovations; and

(2)

the policy of the United States should not be to strip innovators of valid intellectual property protections because it would undermine innovation, weaken the competitiveness of United States businesses, and damage our ability to respond to future pandemics.

Lineage

Jun 17, 2021viewing Introduced in House Mrs. Miller-Meeks (for herself, Mrs. Fischbach, Mr. Jordan, Mr. Norman, Mr. Gibbs, Mr. Van Drew, Mr. Budd, Mr. Hice of Georgia, Mr. Green of Tennessee, Mrs. Hinson, Mr. Rutherford, Mrs. Wagner, Ms. Mace, Mr. Duncan, Mr. Owens, Mr. C. Scott Franklin of Florida, Mr. Burchett, Mr. Hudson, Ms. Malliotakis, Mr. Emmer, and Ms. Cheney) submitted the following resolution; which was referred to the Committee on the Judiciary

Expressing the sense of the House of Representatives that the United States should not waive intellectual property rights relating to COVID–19 vaccines or treatments.

Cite this provision

Incoming references